<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00087347</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000374491</org_study_id>
    <secondary_id>MGH-2004-P-000681/2</secondary_id>
    <secondary_id>NCI-6809</secondary_id>
    <nct_id>NCT00087347</nct_id>
  </id_info>
  <brief_title>Magnetic Resonance Imaging of Lymph Nodes Using Ferumoxytol in Patients With Primary Prostate or Breast Cancer</brief_title>
  <official_title>An NCI-Sponsored Exploratory Study For Determining Optimum Timing For The Imaging Of Intravenous Superparamagnetic Particle Ferumoxytol (Code7228) For The Differentiation of Metastatic and Non Metastatic Lymph Nodes in Patients With Known Primary Cancer Scheduled For Possible Surgical Lymph Node Biopsy/Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <brief_summary>
    <textblock>
      RATIONALE: Diagnostic procedures such as magnetic resonance imaging (MRI) using ferumoxytol&#xD;
      may improve the ability to detect cancer that has spread to the lymph nodes and may help plan&#xD;
      effective cancer treatment.&#xD;
&#xD;
      PURPOSE: This clinical trial is studying how well MRI using ferumoxytol works in detecting&#xD;
      metastases to the lymph nodes in patients with primary prostate cancer or primary breast&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the range of optimal timing for magnetic resonance imaging of lymph nodes&#xD;
           after administration of ferumoxytol, in terms of assessing signal intensity using&#xD;
           pre-defined pulse sequences in regions of interest and visual criteria, in patients with&#xD;
           primary prostate or breast cancer who are scheduled to undergo surgical lymph node&#xD;
           dissection or sampling.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Correlate MRI signal intensity with histological findings in patients undergoing this&#xD;
           procedure.&#xD;
&#xD;
      OUTLINE: This is an open-label, pilot study.&#xD;
&#xD;
      Patients undergo a baseline MRI. Within 24 hours after the baseline MRI, patients receive&#xD;
      ferumoxytol IV over 10-15 seconds (or over 1 hour). Patients then undergo MRI immediately&#xD;
      after ferumoxytol administration (at the discretion of the principal investigator) and then&#xD;
      at 24-28 hours.&#xD;
&#xD;
      Patients are followed at 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-14 patients (6-8 with prostate cancer and 4-6 with breast&#xD;
      cancer) will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ferumoxytol</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>magnetic resonance imaging</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed primary prostate or breast cancer&#xD;
&#xD;
          -  Suspected lymph node metastatic disease by standard MRI or CT scan&#xD;
&#xD;
          -  Scheduled for surgical lymph node dissection or sampling&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  No prior ferritin &gt; 800 ng/mL&#xD;
&#xD;
          -  No prior transferrin saturation &gt; 60%&#xD;
&#xD;
          -  No history of iron overload or hemachromatosis&#xD;
&#xD;
               -  Patients with a clinical history of suspected iron overload or hemachromatosis&#xD;
                  must have normal serum iron, ferritin, and transferrin saturation&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT ≤ 2 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No requirement for monitored anesthesia during MRI&#xD;
&#xD;
          -  No known allergic or hypersensitivity reaction to any of the following&#xD;
             parenterally-administered preparations:&#xD;
&#xD;
               -  Iron&#xD;
&#xD;
               -  Dextran&#xD;
&#xD;
               -  Iron dextran&#xD;
&#xD;
               -  Iron polysaccharide&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception for at least 1 month before and&#xD;
             during study participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  No prior therapy for metastatic disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mukesh Harisinghani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Harisinghani M, Ross RW, Guimaraes AR, Weissleder R. Utility of a new bolus-injectable nanoparticle for clinical cancer staging. Neoplasia. 2007 Dec;9(12):1160-5.</citation>
    <PMID>18084623</PMID>
  </results_reference>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>July 8, 2004</study_first_submitted>
  <study_first_submitted_qc>July 9, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2004</study_first_posted>
  <last_update_submitted>May 12, 2013</last_update_submitted>
  <last_update_submitted_qc>May 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mukesh Harisinghani, MD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>recurrent prostate cancer</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <keyword>stage IV prostate cancer</keyword>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferrosoferric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

